A Phase 1 interventional study of PegIFN-2b (Sylatron®) in Renal Insufficiency, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 17th largest by enrollment, is one of 2 that started in 2011, is one of 25 in phase 1, and was the 10th registered.
1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Merck Sharp & Dohme LLC
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 26 across the 32 interventional studies. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the pharmacokinetics of a single dose of peginterferon alfa-2b (Sylatron®) in healthy participants to that in participants with moderate to severe impairment of kidney function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
Drug: PegIFN-2b (Sylatron®)
Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
Drug: PegIFN-2b (Sylatron®)
Participants with severe renal impairment defined as having a creatinine clearance test value of \<30 mL/min/1.73 m\^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
Drug: PegIFN-2b (Sylatron®)
Single 4.5 μg/kg dose
Also known as: PegIntron®, Peginterferon alfa-2b, SCH 054031, MK-4031
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.
Time frame: From hour 0 (pre-dose) to 288 hours post-dose
AUC From Time 0 to the Last Measurable Sample (AUC0-last)
AUC0-last is a measure of the total amount of drug in the plasma from the dose to the last measurable sample.
Time frame: From hour 0 (pre-dose) up to 288 hours post-dose
Maximum Observed Serum Concentration (Cmax)
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: From hour 0 (pre-dose) to 288 hours post-dose
Time to Maximum Observed Serum Concentration (Tmax)
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
Time frame: From hour 0 (pre-dose) up to 288 hours post-dose
Apparent Terminal Half-life (T1/2)
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%.
Time frame: From hour 0 (pre-dose) up to 288 hours post-dose
Apparent Total Body Clearance (CL/F)
CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).
Time frame: From hour 0 (pre-dose) up to 288 hours post-dose
Apparent Volume of Distribution (Vd/F)
Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.
Time frame: From hour 0 (pre-dose) up to 288 hours post-dose
| Milestone | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Started | 12 | 7 | 6 |
| Completed | 12 | 7 | 6 |
| Not completed | 0 | 0 | 0 |
AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.
| pg*hr/mL | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) | 305315.22 (175840.19 to 530125.58) | 435500.38 (248562.28 to 763030.40) | 658413.69 (395164.74 to 10907032.58) |
AUC0-last is a measure of the total amount of drug in the plasma from the dose to the last measurable sample.
| pg*hr/mL | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| AUC From Time 0 to the Last Measurable Sample (AUC0-last) | 286946.43 (164687.09 to 499967.87) | 408889.84 (232550.52 to 718944.43) | 598863.88 (358269.15 to 1001029.37) |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| pg/mL | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 2547.85 (1115.61 to 5818.84) | 3210.16 (1386.73 to 7431.24) | 3551.03 (1653.85 to 7624.49) |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
| hours | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Time to Maximum Observed Serum Concentration (Tmax) | 12.0 (9.0 to 72.0) | 12.0 (12.0 to 72.0) | 60.0 (24.0 to 96.3) |
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%.
| Hours | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Apparent Terminal Half-life (T1/2) | 41.9 ± 31.9 | 50.7 ± 12.7 | 58.1 ± 17.2 |
CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).
| mL/min | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Apparent Total Body Clearance (CL/F) | 18.5 (10.42 to 32.85) | 12.72 (7.10 to 22.81) | 8.02 (4.71 to 13.64) |
Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.
| Liters | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) | 90.63 (41.76 to 196.69) | 72.26 (32.88 to 158.82) | 55.90 (27.30 to 114.49) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Participants | — | 0/12 (0%) | 12/12 (100%) |
| Participants With Moderate Renal Impairment | — | 0/7 (0%) | 7/7 (100%) |
| Participants With Severe Renal Impairment | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 0/7 | 1/6 |
| Event | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment |
|---|---|---|---|
| PyrexiaGeneral disorders | 9/12 | 6/7 | 4/6 |
| ChillsGeneral disorders | 9/12 | 5/7 | 3/6 |
| HeadacheNervous system disorders | 8/12 | 4/7 | 3/6 |
| NauseaGastrointestinal disorders | 2/12 | 2/7 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/12 | 3/7 | 1/6 |
| MalaiseGeneral disorders | 4/12 | 1/7 | 0/6 |
| VomitingGastrointestinal disorders | 3/12 | 2/7 | 1/6 |
| FatigueGeneral disorders | 0/12 | 2/7 | 0/6 |
| DizzinessNervous system disorders | 0/12 | 2/7 | 1/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/12 | 1/7 | 0/6 |
| Age, Continuous(Years) | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment | Total |
|---|---|---|---|---|
| Mean | 57.33 ± 9.63 | 64.00 ± 6.23 | 52.67 ± 12.74 | 57.83 ± 10.25 |
| Sex: Female, Male(Participants) | Healthy Participants | Participants With Moderate Renal Impairment | Participants With Severe Renal Impairment | Total |
|---|---|---|---|---|
| Female | 1 | 0 | 1 | 2 |
| Male | 11 | 6 | 5 | 22 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b